Our partners at Novartis recently provided the following letter regarding their study of the medication Alpelisib (Vijoice) for the treatment of PROS, called EPIK-P4, in the hopes that the PROS community finds the information helpful and relevant. CSC is sharing the letter with you on their behalf.
A few reminders from Novartis about this letter:
- Content is Novartis confidential and shall not be shared further by the receiver – not for further disclosure, distribution or use without Novartis’ approval.
- This document is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities
- Novartis confidential information and materials shall not be entered, uploaded, or otherwise disclosed into any artificial intelligence tool.
- This document is accurate at the time of presentation; its content may be amended by Novartis in its sole discretion at any time.
- The content of this document is not intended to establish any legally enforceable rights, obligations, or commitments on Novartis.